

Now Available Through Purdue Pharma

"ALOXI® palonosetron hydrochloride

Purdue Pharma is pleased to announce the signing of an agreement with Helsinn Group, giving Purdue Pharma the exclusive rights to distribution and licensing of ALOXI® oral soft capsules and intravenous solution for injection in Canada. Purdue Pharma has assumed all sales, marketing and distribution responsibilities for this product in Canada as of June 6, 2017.

ALOXI® Capsules are Indicated in Adults for:1

 The prevention of acute nausea and vomiting associated with moderately emetogenic cancer chemotherapy

ALOXI® Injection is Indicated in Adults for:1

- The prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy
- The prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high dose cisplatin

ALOXI® is a logical addition to the Purdue Pharma portfolio, which includes other types of medications for patients undergoing cancer treatments.

Route of Administration	Dosage Form/Strength	Non-medicinal Ingredients	
Oral	Soft Capsule (1 pack): 0.5 mg palonosetron (as palonosetron hydrochloride)	Black printing ink, butylated hydroxyanisole, gelatin, glycerine monoglycerides and diglycerides of capryl/capric acid, polyglyceryl oleate, sorbitol, titanium dioxide, water. May contain traces of medium chain triglyceride and lecithin.	
Intravenous	Solution for Injection: 0.25 mg palonosetron (as palonosetron hydrochloride)/5 mL (0.05 mg/mL)	Citrate buffer in water, disodium edetate, and mannitol.	
Purdue Pharma will not be distributing the soft capsule (5 pack) format.			

Consult the Product Monograph at http://purdue.ca/wp-content/uploads/2017/05/Aloxi-English-PM.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-387-4501.

Available to order through your Wholesaler. For inquiries, please contact Purdue Pharma Customer Service at 1 800 387 4501 or customerservice@purdue.ca

Formats	Capsules 0.5 mg	Injection - vial 0.25 mg/5 mL
DIN	02381729	02381710
UPC	060025425776	060025425790





